May 16, 2025

Delandistrogene Moxeparvovec: Efficacy Evidence Questioned

The AAN Guidelines Subcommittee review finds delandistrogene moxeparvovec for DMD failed to meet primary functional outcomes despite FDA approval.

Conexiant

May 15, 2025

First Migraine DHE Autoinjector FDA-Approved

FDA approves Brekiya®, a dihydroergotamine mesylate autoinjector for the acute treatment of migraine with or without aura and cluster headaches in adults.

Conexiant

May 15, 2025

Assistant Professor Salary Gaps Persist Nationwide

Persistent salary disparities by gender, race, and ethnicity were identified among more than 45,000 U.S. assistant professors, with underrepresented in medicine women learning the least across all specialties.

Conexiant

May 15, 2025

Men With Broken Heart Syndrome Have Twice the Mortality Risk: Study

A large U.S. study of nearly 200,000 Takotsubo cardiomyopathy cases found persistently high mortality—especially among men—despite rising incidence and increased recognition from 2016 to 2020.

Conexiant

May 15, 2025

Chikungunya Vaccine Linked to Adverse Events

The FDA and CDC have paused use of the Ixchiq chikungunya vaccine in adults aged 60 and older due to reports of serious postmarketing adverse events.

Conexiant

May 14, 2025

Oral Option Now Available for PPGL

The FDA approved belzutifan as the first oral therapy for advanced pheochromocytoma and paraganglioma in patients aged 12 years and older.

Conexiant

May 13, 2025

Precision Medicine 2050: With Ying Ge

Ying Ge discusses how the use of AI to track health, spot early trends, and customize treatment could transform diagnostics 25 years from now

The Analytical Scientist

May 12, 2025

Effects of Tumor-Infiltrating Clonal Hematopoiesis

In a study reported in The New England Journal of Medicine, Pich et al found that tumor-infiltrating clonal hematopoiesis was associated with an increased risk of death or recurrence among patients wi...

The ASCO Post

May 08, 2025

FDA Warns Physicians of Tianeptine Dangers

The FDA warns physicians about unapproved tianeptine products that are linked to severe adverse events, including dependence, toxicity, and death.

Conexiant